BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24371773)

  • 1. Large granular lymphocytic leukemia associated with Lambert-Eaton Myasthenic Syndrome: A case report.
    Lemal R; Chaleteix C; Minard P; Roche C; Bay JO; Tournilhac O; Lamy T
    Leuk Res Rep; 2013; 2(1):32-3. PubMed ID: 24371773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.
    Takamori M
    J Neuroimmunol; 2008 Sep; 201-202():145-52. PubMed ID: 18653248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    Schoser B; Eymard B; Datt J; Mantegazza R
    J Neurol; 2017 Sep; 264(9):1854-1863. PubMed ID: 28608304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lambert-Eaton myasthenic syndrome, an immune pathology of neuromuscular junctions].
    Honnorat J
    Bull Acad Natl Med; 2014 Feb; 198(2):243-54; discussion 255. PubMed ID: 26263702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome.
    Shimizu F; Takeshita Y; Sano Y; Hamamoto Y; Shiraishi H; Sato T; Yoshimura S; Maeda T; Fujikawa S; Nishihara H; Kitanosono H; Tsujino A; Motomura M; Kanda T
    Brain; 2019 Aug; 142(8):2253-2264. PubMed ID: 31236596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy.
    Hülsbrink R; Hashemolhosseini S
    Clin Neurophysiol; 2014 Dec; 125(12):2328-36. PubMed ID: 25065299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
    Titulaer MJ; Lang B; Verschuuren JJ
    Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Favourable outcome after treatment with rituximab in a case of seronegative non-paraneoplastic Lambert-Eaton myasthenic syndrome].
    Boutin E; Rey C; Romeu M; Pouget J; Franques J
    Rev Med Interne; 2013 Aug; 34(8):493-6. PubMed ID: 23759215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular immunology of voltage-gated calcium channel and Lambert-Eaton myasthenic syndrome].
    Iwasa K; Komai K; Yasukawa Y; Maruta T; Takamori M
    Nihon Rinsho; 1997 Dec; 55(12):3322-30. PubMed ID: 9436458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lambert-Eaton syndrome antibodies target multiple subunits of voltage-gated Ca2+ channels.
    Hajela RK; Huntoon KM; Atchison WD
    Muscle Nerve; 2015 Feb; 51(2):176-84. PubMed ID: 24862203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lambert-Eaton Myasthenic Syndrome.
    Kesner VG; Oh SJ; Dimachkie MM; Barohn RJ
    Neurol Clin; 2018 May; 36(2):379-394. PubMed ID: 29655456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of intravenous immunoglobulin for treatment of Lambert-Eaton myasthenic syndrome without anti-presynaptic P/Q-type voltage-gated calcium channel antibodies: a case report.
    Okada A; Koike H; Nakamura T; Motomura M; Sobue G
    Neuromuscul Disord; 2015 Jan; 25(1):70-2. PubMed ID: 25444432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Unique Case of Non-paraneoplastic Lambert-Eaton Myasthenic Syndrome Treated With Subcutaneous Immunoglobulin: A Case Report and Review of Literature.
    Park SK; Taylor MG
    Cureus; 2024 May; 16(5):e60773. PubMed ID: 38903354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lambert-Eaton myasthenic syndrome: diagnosis and treatment].
    Motomura M; Iwanaga H
    Clin Calcium; 2001 Nov; 11(11):1468-74. PubMed ID: 15775666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lambert-Eaton myasthenic syndrome (LEMS)].
    Suzuki S
    Brain Nerve; 2010 Apr; 62(4):419-26. PubMed ID: 20420183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low specificity of voltage-gated calcium channel antibodies in Lambert-Eaton myasthenic syndrome: a call for caution.
    Di Lorenzo R; Mente K; Li J; Shayya L; Rae-Grant A; Li Y; Jammoul A
    J Neurol; 2018 Sep; 265(9):2114-2119. PubMed ID: 29987589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.
    Wang C; Chen S; Feng B; Guan Y
    Muscle Nerve; 2014 Mar; 49(3):325-8. PubMed ID: 24464710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.
    Motomura M; Lang B; Johnston I; Palace J; Vincent A; Newsom-Davis J
    J Neurol Sci; 1997 Mar; 147(1):35-42. PubMed ID: 9094058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased frequency of HLA class II alleles DRB1*0301 and DQB1*0201 in Lambert-Eaton myasthenic syndrome without associated cancer.
    Parsons KT; Kwok WW; Gaur LK; Nepom GT
    Hum Immunol; 2000 Aug; 61(8):828-33. PubMed ID: 10980394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An autoimmune channelopathy associated with cancer: Lambert-Eaton myasthenic syndrome.
    Takamori M
    Intern Med; 1999 Feb; 38(2):86-96. PubMed ID: 10225662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.